MapLight Therapeutics, Inc. (MPLT) Financial Ratios
3 years of historical data (2022–2024)
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
10.33
—
5yr avg: N/A
ROE
↑
-83.2%
↓+28% vs avg
5yr avg: -116.0%
30Y Low-144%·High-83%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MPLT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MapLight Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $1.3B | — | — | — |
| Enterprise Value | $1.3B | — | — | — |
| P/E Ratio → | -15.36 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | 10.33 | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MPLT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
MPLT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -83.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | -83.2% | -83.2% | -120.9% | -143.8% |
| ROA | -68.0% | -68.0% | -85.2% | -76.2% |
| ROIC | -153.7% | -153.7% | — | — |
| ROCE | -83.9% | -83.9% | -110.7% | -116.6% |
MPLT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $38M exceeds total debt of $7M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.08 | 0.30 |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | -0.27 | -1.04 | -1.03 |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | — | — | — | — |
Net cash position: cash ($38M) exceeds total debt ($7M)
MPLT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
MapLight Therapeutics, Inc.'s current ratio of 7.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.54x to 7.20x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 7.20 | 7.20 | 5.69 | 2.54 |
| Quick Ratio | 7.20 | 7.20 | 5.69 | 2.54 |
| Cash Ratio | 6.83 | 6.83 | 5.43 | 2.20 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
MPLT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MapLight Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — |
| Shares Outstanding | — | $41M | $41M | $41M |
Peer Comparison
Compare MPLT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MPLTYou | $1B | -15.4 | — | — | — | — | -83.2% | -153.7% | — |
 ACNB | $539M | 14.5 | 15.9 | 10.2 | 73.7% | 27.3% | 10.2% | 5.3% | 6.2 |
 PTGX | $7B | -49.8 | — | 117.2 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 TERN | $5B | -51.4 | — | — | — | — | -14.2% | -24.7% | — |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 NRXP | $91M | -2.4 | — | — | — | -1324.4% | — | — | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 ACAD | $4B | 9.3 | 25.5 | 34.8 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.7 | 6.6 | 8.3 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $10B | -25.4 | — | — | — | — | -45.8% | -65.0% | — |
 NRXS | $97M | -8.3 | — | — | 84.2% | -219.4% | -285.4% | — | — |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 3 years · Updated daily
See MPLT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MPLT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MPLT vs ACNB
Side-by-side business, growth, and profitability comparison vs ACNB Corporation.
Start ComparisonMPLT — Frequently Asked Questions
Quick answers to the most common questions about buying MPLT stock.
What is MapLight Therapeutics, Inc.'s P/E ratio?
MapLight Therapeutics, Inc.'s current P/E ratio is -15.4x. This places it at the 50th percentile of its historical range.
What is MapLight Therapeutics, Inc.'s ROE?
MapLight Therapeutics, Inc.'s return on equity (ROE) is -83.2%. The historical average is -116.0%.
Is MPLT stock overvalued?
Based on historical data, MapLight Therapeutics, Inc. is trading at a P/E of -15.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.